Tag Archives: Aduhelm

Business Management, Medicine

The FDA responds to blistering complaints

June 29, 2021 Roy A. Ackerman, Ph.D., E.A. 8 Comments

I devoted two posts to the Aduhelm/Alzheimer’s controversy. (The most recent one was yesterday.) Today, I will post (the FDA verbiage in black ink, with my editorial comments in red print) the FDA’s reasoning (sic) as to why it overrode the recommendations of its qualified experts.

Continue reading The FDA responds to blistering complaints →

Aduhelm controversy- part 2

June 28, 2021 Roy A. Ackerman, Ph.D., E.A. 23 Comments

We spoke about the Aduhelm fiasco about two weeks ago.

Continue reading Aduhelm controversy- part 2 →

Hope or Chimera for Alzheimer’s Patients?

June 17, 2021 Roy A. Ackerman, Ph.D., E.A. 3 Comments

Hmm. Is this good news or not?

The FDA (Food and Drug Administration) has just approved aducanumab (Aduhelm) for Alzheimer’s. Of course, if you are Biogen, this is great news. But, since the data is – how do I say this?- less than emphatic- will this really help patients?

Continue reading Hope or Chimera for Alzheimer’s Patients? →